Background
Pridopidine is an orally administered small molecule that crosses the blood-brain barrier, reaching the brain, and binds to the dopamine D2/D3 and sigma-1 (S1R) receptors. Pridopidine is owned by Prilenia, who describes it as a potent and selective S1R agonist (activator) that rebalances calcium, which reduces intracellular (endoplasmic reticulum) stress, and restores synaptic function. These actions collectively contribute to the hypothesized neuroprotective effects of pridopidine, potentially restoring connectivity between neurons and maintaining their viability (Gracehv, Meyer et al., 2020; Waters et al., 2018).
Preclinical studies have shown beneficial effects of pridopidine in cellular and mouse models of several neurodegenerative disorders (Ryskamp et al., 2019). It was originally studied as a treatment for Huntington’s Disease. However, given its characteristics it was thought to potentially also have an effect on ALS/MND disease mechanisms. In SOD1 mice pridopidine showed improvement of motor symptoms but no effect on overall survival (Ref: Estévez‐Silvaet al., 2022).
Trial Design & Results
In 2022, a phase 2/3 clinical trial was conducted through the HEALEY platform in 163 people with ALS/MND. The trial was randomized at a 3:1 ratio to receive active pridopidine or a matching placebo. It was a 6-month, double-blind, placebo-controlled study that rolled over into an open label extension (Ref: Quintana et al., 2023).
The drug or placebo were administered orally twice a day. The measured primary endpoint was change from baseline through 24 weeks in the total ALS functional rating scale revised (ALSFRS-R) score.
In February 2023, a press release from the Healey & AMG Center and the Northeast ALS Consortium (NEALS) indicated that the primary endpoint was not met; however, pridopidine was considered safe and well tolerated. This was subsequently published in 2025. A post hoc analysis published in 2026 revealed that within a very small subset of participants, with definite or probable ALS/MND combined with being early, fast progressors (pridopidine n=20; placebo n=14), those treated with pridopidine had less decline in speech. Additional post hoc analyses in the same subgroup demonstrated ALSFRS-R (Δ5.2, p=0.04) and quality of life measures that favoured pridopidine over placebo. While these results are potentially intriguing, it is important to note that post hoc data from small subgroups can be misleading and require confirmation in larger studies.
A global phase 3 clinical trial for pridopidine in ALS/MND has been announced. The PREVAiLS trial is currently recruiting will examine the effectiveness of pridopidine in ALS/MND in 500 participants over a 12-month period.
Summary
Data shows that pridopidine appears safe and well tolerated at the therapeutic dose. The efficacy of pridopidine was tested through the HEALEY ALS platform but did not meet its primary endpoint. Post hoc analyses from the trial suggests there may be some potential benefit to speech, quality of life, and ALSFRS-R score. Due to the very small subset of participants used in these analyses, this potential benefit should be interpreted with caution.
The SAC believes that, to date, there is insufficient evidence to conclude that pridopidine provides any clinical benefit to people living with ALS and looks forward to the results of the Phase 3 clinical trial that will provide clearer evidence for/against its efficacy.
International Alliance of ALS/MND Associations
April 2026
Disclaimer: Consult with a healthcare professional to determine if you could potentially participate in a pridopidine clinical trial. Always disclose your medical history, including any drugs, natural supplements, or herbal medicines currently being used.
The original language of communication is English and any translation cannot be guaranteed for accuracy of messaging.